Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 52Tumor-Agnostic 3Gastrointestinal 3Thoracic 2Other solid neoplasm 2Head & Neck 2Breast 2Gynecologic 1Dermatologic 1

Conditions

Metastatic Urothelial Cancer and Other Malignant Solid Tumors 1Advanced Solid Tumor 1

Interventions

Cisplatin 145pembrolizumab 129Carboplatin 125Injections 108Pemetrexed 97Paclitaxel 97Gemcitabine 85Irinotecan 75Nivolumab 71Cyclophosphamide 71Docetaxel 68Bevacizumab 57Oxaliplatin 49Fluorouracil 48atezolizumab 46Capecitabine 46Etoposide 42Leucovorin 41tislelizumab 40toripalimab 36fludarabine 32Ipilimumab 30Drug Therapy 30Topotecan 29durvalumab 28Vincristine 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 26Specimen Handling 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × enfortumab vedotin × Other solid neoplasm × Clear all
NCT07157956 2025-09-05

CVL006-T1002

Convalife (Shanghai) Co., Ltd.

Phase 1/2 Not yet recruiting
318 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT02091999 2024-11-01

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Astellas Pharma Inc

Phase 1 Completed
213 enrolled
GenitourinaryOther solid neoplasm

Metastatic Urothelial Cancer and Other Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡